Cash and cash equivalents were $278.6 million as of December 31, 2023, compared to $326.4 million as of December 31, 2022. The Company currently expects its cash runway to extend into the fourth quarter of 2025.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ADCT:
- ADC Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
- ADC Therapeutics Ltd (ADCT) Q4 Earnings Cheat Sheet
- ADC Therapeutics to Participate in the Guggenheim 5th Annual Healthy Altitudes Summit
- ADC Therapeutics to Host Fourth Quarter and Year-End 2023 Financial Results Conference Call on March 13, 2024
- ADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cancer Research (AACR) Annual Meeting